Key Takeaways
Zealand Pharma A/S and its partner Roche Holding AG are advancing their weight-loss drug candidate, petrelintide, into late-stage testing, positioning it as a potential challenger in the multi-billion dollar obesity market currently dominated by GLP-1 therapies. The move to Phase 3 trials, planned for the second half of 2026, follows promising Phase 2 results showing significant weight loss with minimal side effects.
“By delivering exceptional tolerability and desired weight loss without disrupting daily life, we aim to redefine the weight management experience for people living with overweight and obesity," Adam Steensberg, President and Chief Executive Officer of Zealand Pharma, said in a statement.
Petrelintide is a long-acting amylin analog, a hormone co-secreted with insulin that helps regulate appetite by restoring sensitivity to the satiety hormone leptin. In the ZUPREME-1 Phase 2 trial, the drug demonstrated double-digit weight loss while maintaining a safety profile comparable to a placebo. The upcoming Phase 3 program will further evaluate the efficacy and safety of the once-weekly subcutaneous injection in adults with obesity or who are overweight with related health issues. Zealand and Roche are also planning a Phase 2 trial in the second quarter of 2026 to test petrelintide in combination with Roche's GLP-1/GIP agonist, enicepatide (CT-388).
The collaboration with Roche significantly de-risks the path to market for Zealand Pharma (Nasdaq: ZEAL), providing manufacturing and commercial scale. Success in Phase 3 could unlock a significant revenue stream in a market projected to surpass $100 billion by 2030. The focus on high tolerability is a key strategic differentiator, targeting a segment of patients who cannot tolerate the gastrointestinal side effects common with GLP-1 drugs from competitors like Novo Nordisk A/S and Eli Lilly and Co. While GLP-1s have proven highly effective, a significant number of patients discontinue treatment due to side effects, creating an "urgent unmet medical need" for durable weight loss maintenance, according to recent studies.
The advancement of petrelintide opens a new front in the battle for the lucrative obesity drug market. Amylin-based therapies may offer a more tolerable weight-loss alternative for a broader patient population. This could enhance future revenues and net margins as the market matures, especially if the drug can demonstrate long-term adherence. Zealand Pharma, a biotech with more than 25 years of peptide R&D, has over 10 drug candidates that have entered clinical development, with two products already on the market and three in late-stage development.
The competitive landscape includes other oral and injectable treatments. Eli Lilly's orforglipron, an oral GLP-1 agonist, has also shown significant weight loss across all BMI categories in its ATTAIN-1 trial. The potential for combination therapies, like petrelintide with enicepatide, represents another key area of development, aiming to improve efficacy and durability of weight loss. As the market evolves, the focus may shift from pure weight loss to long-term, tolerable solutions that can prevent weight regain, a common issue after stopping treatment.
This article is for informational purposes only and does not constitute investment advice.
